Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens

Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens

Cytomegalovirus (CMV) reactivation during chemotherapy or after organ or hematopoietic stem cell transplantation is a major cause of morbidity and mortality, and the risk of reactivation increases with patients’ age. Bendamustine, an alkylating agent currently used for treatment of indolent and aggr...

Full description

Bibliographic Details
Main Authors: Pezzullo Luca, Giudice Valentina, Serio Bianca, Fontana Raffaele, Guariglia Roberto, Martorelli Maria Carmen, Ferrara Idalucia, Mettivier Laura, Bruno Alessandro, Bianco Rosario, Vaccaro Emilia, Pagliano Pasquale, Montuori Nunzia, Filippelli Amelia, Selleri Carmine
Format: Article
Language:English
Published: De Gruyter 2021-04-01
Series:Open Medicine
Subjects:
cytomegalovirus
non-hodgkin lymphoma
chemotherapy
immunity
Online Access:https://doi.org/10.1515/med-2021-0274

Internet

https://doi.org/10.1515/med-2021-0274

Similar Items